Xlife Sciences: Valuation Report 2022 Confirms And Emphasizes Longterm Portfolio Potential
Xlife Sciences AG (SIX: XLS) today published its full Valuation Report 2022, which evaluates a portfolio of companies until the end of 2022. The valuation was carried out by independent consultancy Cylad Experts and covers 20 companies from 26 Xlife projects Sciences.[1] ] Valuation is primarily based on risk-adjusted net present value (NPV) commonly used … Read more